IMPORTANCE Long QT syndrome (LQTS) is caused by several ion channel genes, yet risk of arrhythmic events is not determined solely by the responsible gene pathogenic variants. Female sex after adolescence is associated with a higher risk of arrhythmic events in individuals with congenital LQTS, but the association between sex and genotype-based risk of LQTS is still unclear.
L ong QT syndrome (LQTS) is typically characterized by QT interval prolongation on electrocardiogram results associated with syncope or sudden cardiac death in young individuals when prolongation of the QT interval induces torsade de pointes, a polymorphic ventricular tachycardia that can degenerate into ventricular fibrillation. 1 Long QT syndrome is caused by several ion channel genes, the most common of which are LQTS type 1 (LQT1) on the other hand, mexiletine hydrochloride therapy can effectively shorten the QT interval and improve prognosis.
12,13
Thus, genetic studies can help identify appropriate genespecific therapy and management for patients with LQTS. However, the current biophysical assessments of the electrophysiological effects of LQTS-causing variants do not completely support a genotype-phenotype correlation. Female sex after adolescence is associated with a higher risk of arrhythmic events in congenital LQTS, 7,14 but the association between sex and genotype-based risk of LQTS is still unclear. Furthermore, to our knowledge, there are few systematic cohort studies on the genotype-phenotype correlation in Asian populations. Here, we hypothesized that LQTS variant site-specific risk of arrhythmic events was influenced by sex. In this LQTS genetic registry study in an Asian population, which is the largest such registry to our knowledge, we examined the association between sex and LQTS pathogenic variant site as it pertains to the risk of life-threatening arrhythmias.
Genetic Analysis
Analysis of DNA was conducted by extracting genomic DNA from the leukocytes, then using a combination of polymerase chain reaction, either denaturing high-performance liquid chromatography or single-stranded conformation polymorphism and DNA sequencing. Genetic screening of all probands was performed at the institutions listed in the eAppendix in the Supplement according to the conventional Sanger method, as described previously. 15 Probands with a variant at either the first or the last 2 nucleotides of a particular exon were included because a substitution of such portions can alter messenger RNA splicing. A variant with high minor allele frequency (>0.001) in healthy cohorts including ethnically matched ones (gnomAD [Genome Aggregation Database] : http://gnomad.broadinstitute. org/; and TogoVar [National Bioscience Database Center's integrated database of Japanese genomic variation] https://togovar. biosciencedbc.jp/) was considered a benign variant and was excluded from our study. We then evaluated detected variants as listed in the eAppendix in the Supplement. The pathogenic variants are presented in eTables 1-4 in the Supplement by coding effect, location, and frequency.
Statistical Analysis
Statistical analysis was conducted from January 18 to October 10, 2018. The primary end point was the time from birth until the first cardiac event (syncope, ventricular fibrillation [VF] , aborted cardiac arrest, or sudden cardiac death), censoring at loss to follow-up, or age 50 years, whichever occurred first. The restricted, more severe secondary end point was VF, cardiac arrest, or death, whichever occurred first. The JMP Pro, version 12.2.0, software (SAS Institute Inc) was used for statistical analyses. Continuous variables were expressed as the mean and SD or as the median with interquartile range. Categorical variables were expressed as numbers and percentages. We compared continuous variables using unpaired t tests or the Welch t test, based on the type of distribution. We compared categorical variables using the Pearson χ 2 test when appropriate or the Fisher exact test.
Survival curves were plotted using Kaplan-Meier methods, and survival difference was analyzed by log-rank test and Cox proportional hazards regression model. All P values were from 2-sided tests and results were deemed statistically significant at P < .05. The Cox proportional hazards regression model was used to evaluate the contribution of clinical and genetic factors to the risk of the first occurrence of time-dependent cardiac events from birth to age 50 years. Cox proportional hazards regression models were stratified by sex to relax the assumption of proportional hazards by allowing sex-specific nonparametric baseline hazard functions for males and females.
Results

Clinical and Genotype Differences
As given in Table 1 Kaplan-Meier cumulative analysis of first arrhythmic events revealed that syncope or lethal cardiac events occurred between ages 5 and 15 years in those with LQT1, whereas in patients with LQT2 such events occurred after the teen years and gradually increased in frequency with age (eFigure 2A in the Supplement). After age 25 years, the cumulative probability of syncope or lethal cardiac events was higher in those with LQT2 than in those with LQT1. Those events were significantly less common in patients with LQT3 than in those with LQT1 or LQT2, yet they could occur in patients with LQT3 at any age, even in infancy. On the other hand, rates and timing of VF and cardiac arrest were similar between the genotypes (eFigure 2B in the Supplement). Thus, the rate of lethal cardiac events was higher in patients with LQT3 by χ 2 test) ( Figure 1B and E). This association might be related to a hormonal sex difference. In patients with LQT3, on the other hand, no sex difference was observed before or after puberty ( Figure 1C and F).
Variant Site-Specific Differences and Sex Differences in Cardiac Events
In patients with LQT1, pathogenic variants in the pore region (segment 5 to segment 6 [S5-pore-S6]) and nonpore membrane spanning region were associated with higher risk of arrhythmic events than were variants in the N/C-terminus (HR, 1.60; 95% CI, 1.19-2.17; P = .002) ( Figure 2A) ; lethal events were particularly frequent in patients with LQT1 with the S5-pore-S6 pathogenic variant ( Figure 2B ). In patients with LQT2, those with S5-pore-S6 pathogenic variants had higher risk of arrhythmic events than did those with variants in other regions (HR, 1.88; 95% CI, 1.44-2.44; P < .001) ( Figure 2C ); in contrast to patients with LQT1, however, lethal cardiac events were not more common in those with LQT2 with pore site pathogenic variants ( Figure 2D ). In patients . N/C-term indicates N-terminus or C-terminus variants; nonpore MS, membrane-spanning variants excluding the S5-pore-S6; and S5-pore-S6, variants of pore site and segment 5 (S5) to segment 6 (S6).
with LQT3, nearly half (50 of 116 [43.1%]) the patients had the E1784K variant, but patients with S5-pore-S6 pathogenic variants (21 of 116 [18.1%]) had a much higher risk of cardiac events than did those with others (HR, 4.2; 95% CI, 2.09-8.36; P < .001). Most pathogenic variants in the N/C-terminus were the E1784K variant and carried a lower risk of arrhythmic events than those of other regions ( Figure 2E and F) .
We further investigated sex differences in variant sitespecific cumulative first cardiac events in patients with LQT1 and those with LQT2. In male patients with LQT1, no significant difference between variant sites was observed with regard to first events ( Figure 3A) ; in female patients with LQT1, in contrast, there was a significant difference between variant sites with regard to first events: a significantly higher risk of arrhythmic events was associated with the S5-pore-S6 region ( Figure 3B ). In patients with LQT2, a significantly higher risk of arrhythmic events was associated with the S5-pore-S6 pathogenic variant in both sexes ( Figure 3C and D) . However, the mean (SD) event-free rate at age 30 years in males was 0.37 (0.08) for the S5-pore-S6 pathogenic variant, 0.64 (0.10) for the nonpore membrane spanning variant, and 0.71 (0.06) for the N/C-terminus variant. In contrast, the mean (SD) event-free rate at age 30 years in females was 0.38 (0.03) for the S5-pore-S6 pathogenic variant, 0.39 (0.10) for the nonpore membrane spanning variant, and 0.43 (0.04) for the N/C-terminus variant. Thus, the variant site-specific difference in risk was much greater in males with LQT2 compared with females with LQT2 because female sex itself was a greater risk in LQT2.
Multivariable Cox proportional hazards regression analysis was also investigated for the first cardiac events including syncope, VF, or cardiac arrest ( Table 2 ). The prolongation of the QTc interval was associated with cardiac events in patients of both sexes with LQT1 (males: hazard ratio [HR], 1.07; 95% CI, 1.02-1.12; and females: HR, 1.06; 95% CI, 1.02-1.10); however, in patients with LQT2, prolongation of the QTc interval was seen only in males (HR, 1.09; 95% CI, 1.03-1.15) but not in females (HR, 1.03; 95% CI, 0.99-1.06). In variant location, the pore region was associated with a higher risk of arrhythmic events in females with LQT1 (HR, 1.88; 95% CI, 1.02-2.93; P = .006) but not in males with LQT1 (HR, 1.28; 95% CI, 0.75-2.17; P = .36). In patients with LQT2, the pore regionspecific difference was observed both in males (HR, 1.99; 95% CI, 1.11-3.57; P = .02) and females (HR, 1.64; 95% CI, 1.18-2.27; P = .003). 
Discussion
This multicenter registry is, to our knowledge, the first major cohort study of congenital LQTS in an Asian population and includes more than 1100 Japanese patients with LQTS or families who had the same pathogenic variant. Overall, our clinical findings, including those related to cardiac events in each LQTS genotype, are similar to those previously reported in registries of white patients or international registries. 6, 8, 16 However, pathogenic variants are not exactly equivalent between races/ethnicities, 17 and some specific variants are well observed in Asian (Japanese) populations. Thus, our genetic database may aid in diagnosis and risk stratification for Asian patients with LQTS. Second, this study focused on how sex differences were associated with the effect of different variant sites in the prognosis of LQTS. In patients with LQT1, higher risks of arrhythmic events associated with pore site pathogenic variants were observed only in females. In patients with LQT2, although the variant site-specific higher risk in the S5-pore-S6 region was observed in both sexes, female sex particularly after puberty was associated with a greater risk of arrhythmic events compared with male sex regardless of the QTc interval. In patients with LQT3, on the other hand, no sex difference was seen. Not only genotype-specific but also pathogenic variant site-specific differences in risk of arrhythmic events have been reported in patients with LQT1 and LQT2, 9,10 suggesting that variants located in the pore sites of ion channels were associated with significantly higher risk of arrhythmic events than were variants in nonpore sites. Pore site pathogenic variants had already been reported in 118 Japanese patients with LQT2, 18 with a risk of arrhythmic events similar to that seen in an international registry. 10 The present Japanese LQTS registry also demonstrates that, as in the international registry, pore site pathogenic variants are associated with a higher risk of arrhythmic events in patients with LQT1 and LQT2, 9,10 especially those with LQT2.
Barsheshet et al 19 have previously reported that missense variants in C-loops of KCNQ1 channels were more highly arrhythmogenic than those in the membrane spanning location and other locations. In this Japanese registry, however, both C-loop and membrane spanning variants were equally higher risk compared with the N/C-terminus variants (eFigure 3 in the Supplement). Female sex is well known to be a modifier for prolongation of the QT interval and arrhythmic events after the onset of adolescence.
7 In our study, female patients with LQT1 and LQT2 after puberty had significantly higher risks of arrhythmic events compared with male patients ( Figure 1D and E). Furthermore, higher risk of arrhythmic events associated with the pore site LQT2 variant was observed in both sexes, but cumulative risk of arrhythmic events of other regions was higher in females with LQT2 than in males with LQT2 ( Figure 3C and D), since female sex itself is already associated with elevated risk even in cases of nonpore pathogenic variants. In LQT1, in contrast, female patients with pore site variants had noticeably higher risk of arrhythmic events than did those with nonpore site variants (Figure 3) , whereas no variant site-specific difference was observed in male patients with LQT1 ( Figure 3A) . Thus, the variant sitespecific differences in risk of arrhythmic events in patients with LQTS are sex dependent. Our results further advance those of previous studies 20, 21 and suggest that combined assessment of sex and variant location and function data is useful to identify high-risk patients with LQT1 and LQT2. On the other hand, no sex-specific difference was observed in patients with LQT3. In the present registry, nearly 40% of patients with LQT3 had the E1784K variant, but these patients exhibited a lower risk of arrhythmic events, whereas 
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those with pore site pathogenic variants had significantly higher risk of arrhythmic events ( Figure 2E and F). Prolonged QTc and syncope predispose patients with LQT3 to lifethreatening cardiac events. However, a recent article has suggested that β-blocker therapy reduces this risk in females; its efficacy in males, however, could not be determined conclusively because of the small number of events.
22
Limitations
This study gathered 16 individuals with compound heterozygous pathogenic variants but excluded them from analysis. This study has not taken into account whether polymorphism is associated with either lengthening or shortening of the QT interval or any effect that polymorphism may have on risk of arrhythmic events. 23 Not only pathogenic variants but also rare single-nucleotide polymorphisms can affect the QT interval and risk of arrhythmias. Because we have access to follow-up data for many of the registry patients, our further investigations will aim to reveal the efficacy of β-blocker therapy as associated with genotypes, pathogenic variants, rare single-nucleotide polymorphisms, and sex differences. Second, although the S5-pore-S6 variant of LQT3 in this registry was not always associated with Brugada syndrome or other conduction disorders, patients with the SCN5A variant have a potential for mixed phenotypes, which are hard to be separated. Thus, we could not completely exclude the possibility of the mixed phenotype as the cause of lethal ventricular arrhythmias.
Third, this Japanese LQTS registry enrolled patients with a relatively recent diagnosis of LQTS (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) . On the other hand, a previous study 7 had already reported a greater risk of LQT1 in prepubertal boys than in prepubertal girls, which may lead to more significant limitation in exercise in school-aged children, especially for boys; therefore, this limitation may have resulted in no sex difference at risk before age 15 years in this Japanese registry.
Conclusions
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